Dermatological complications and safety of anti-TNF treatments

被引：71

作者：

Kerbleski, Joseph F. ^{[1
]}

Gottlieb, Alice B. ^{[1
]}

机构：

[1] Tufts Med Ctr, Dept Dermatol, Boston, MA 02111 USA

来源：

GUT | 2009年 / 58卷 / 08期

关键词：

TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; INFUSION REACTIONS; FACTOR-ALPHA; COMBINATION THERAPY; CROHNS-DISEASE; RISK-FACTORS; INFLIXIMAB; INFECTIONS; MANAGEMENT;

D O I：

10.1136/gut.2008.163683

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

It has been reported that tumour necrosis factor (TNF) inhibitors have adverse side-effects including infections, malignancies, demyelinating disease, and induction of autoimmune conditions. Dermatological complications of anti-TNF therapy include injection site reactions, cutaneous infections, allergic rashes, psoriasis, non-melanoma skin cancer (NMSC), and rare reports of lupus-like syndrome, erythema multiforme (EM), Steven's Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).

引用

页码：1033 / 1039

页数：7

共 50 条

[31] Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience
Freling, Estelle
Baumann, Cedric
Cuny, Jean-Francois
Bigard, Marc-Andre
Schmutz, Jean-Luc
Barbaud, Annick
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (08): : 1186 - 1196
[32] EFFICACY AND SAFETY OF ABATACEPT IN PATIENTS WITH RA AND AN INADEQUATE RESPONSE TO ANTI-TNF THERAPY BY NUMBER OF PRIOR ANTI-TNF THERAPIES USED
Schiff, M.
Le Bars, M.
Gaillez, C.
Wu, G.
Poncet, C.
Genovese, M. C.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S29 - S30
[33] Identifying the targets of thalidomide and anti-TNFα antibody treatments in ankylosing spondylitis (AS).
Huang, F
Gu, J
Braun, J
Sieper, J
Yu, DT
ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S396 - S396
[34] From corticosteroids to Anti-TNF treatments, when dependence takes over
Bourreille, A
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (8-9): : 696 - 698
[35] Biological Treatments in Behcet's Disease: Beyond Anti-TNF Therapy
Caso, Francesco
Costa, Luisa
Rigante, Donato
Lucherini, Orso Maria
Caso, Paolo
Bascherini, Vittoria
Frediani, Bruno
Cimaz, Rolando
Marrani, Edoardo
Nieves-Martin, Laura
Atteno, Mariangela
Raffaele, Carmela G. L.
Tarantino, Giusyda
Galeazzi, Mauro
Punzi, Leonardo
Cantarini, Luca
MEDIATORS OF INFLAMMATION, 2014, 2014
[36] Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification
de la Torre, Inmaculada
Valor, Lara
Carlos Nieto, Juan
Hernandez, Diana
Martinez, Lina
Gonzalez, Carlos M.
Monteagudo, Indalecio
Lopez Longo, Javier
Montoro, Maria
Carreno, Luis
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (03) : 407 - 414
[37] Systematic review: Safety and efficacy of anti-TNF in elderly patients
Busquets, Noemi
Carmona, Loreto
Suris, Xavier
REUMATOLOGIA CLINICA, 2011, 7 (02): : 104 - 112
[38] ABATACEPT AND ANTI-TNF MONOCLONAL ANTIBODIES: EFFICACY AND SAFETY COMPARISONS
Schiff, M.
Dougados, M.
Fleischmann, R.
Fay, J.
Maldonado, M.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 461 - 462
[39] Safety of anti-TNF biologics in paediatric inflammatory bowel disease
Ruemmele, Frank M.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (11): : 813 - 815
[40] Safety of anti-TNF therapy in RA patients with Hepatitis C
Pittman, Cory B.
Joseph, Amy M.
Mody, Ami
Gutierrez, Ernesto
Ali, Zarmeena
Richards, John Steuart
Kerr, Gail S.
Reimold, Andreas
Rangan, Bavana V.
Hooker, Roderick
McTigue, Joan
Edwards, Larry
Robinson, Nichole
Eisen, Seth
Fimmel, Claus
Kanwal, Fasiha
Ranganathan, Prabha
ARTHRITIS AND RHEUMATISM, 2007, 56 (12): : 4279 - 4279

← 1 2 3 4 5 →